Blackber
Experienced Member
- Reaction score
- 604
I couldn't read the original article but if Hellouser likes it, it's fine by me.
These guys were always my favourites, let's keep our fingers crossed.
This is probably a stupid question but here it goes: Why only in Japan? Any chance we could get this in Europe and when?
Replicel has a licensing agreement with Shiseido for parts of Asia - most importantly Japan because of Japan's new stem cell friendly regulations. If the product works I'm sure other countries will eventually get Replicel so if repeat injections are required chances are we won't have to go back to Japan every single time.
Shiseido is also paying for all the clinical trials in Japan. From what I've read Replicel doesn't seem to want to run their own clinical trials because they cost a lot of money. They prefer to license out their technology to other/bigger partners for a fee or a percentage of their sales thus keeping their (Replicel's) costs low which is a pretty smart business model for a new company, they're putting the financial burden on Shiseido. Again I can't see Shiseido taking on those costs AND building a facility in Kobe dedicated solely for this treatment if they weren't impressed with Replicel.
Seems like it is because Japan has new laws for that kind of research (stem cells) which makes it faster for companies to release their products.
I remember listening to an interview with Lee Buckler where he said Japan was a priority for them because their regulations allow the possibility of bringing their treatments to commercialization more quickly. Theoretically the faster Replicel/Shiseido comes to market, the faster Replicel makes money, the more confident they'll feel about spending money to bring Replicel to clinical trials in other countries.